NCT01119768

Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients

A Multicenter, Randomized, Open-label Phase IV Study Exploring Symptom Control Rate in Co-diagnosed NERD and Chronic Gastritis Patients Treated With 8 Weeks Esomeprazole Treatment Regimen and 2 Weeks Esomeprazole Treatment Regimen

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 305 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To compare the symptom control rate between 8 weeks esomeprazole treatment regimen group and 2 weeks esomeprazole treatment regimen group in co-diagnosed NERD and chronic gastritis patients, as evaluated by GerdQ after 24 weeks maintenance treatment/follow up.

Detailed description

A multicenter, randomized, open-label Phase IV study exploring symptom control rate in co-diagnosed NERD and chronic gastritis patients treated with 8 weeks esomeprazole treatment regimen and 2 weeks esomeprazole treatment regimen.

Conditions

• Non Erosive Reflux Disease
• Chronic Gastritis

Interventions

Type	Name	Description
DRUG	Esomeprazole	20mg Esomeprazole once daily, 8 weeks and 24 weeks on-demand treatment
DRUG	Esomeprazole	20mg Esomeprazole once daily, 2 weeks and 24 weeks follow up

Timeline

• Start date: 2010-04-01
• Primary completion: 2011-06-01
• Completion: 2011-06-01
• First posted: 2010-05-10
• Last updated: 2012-09-28
• Results posted: 2012-09-28

Locations

8 sites across 1 country: China